Advanced Solid Tumor
Conditions
Interventions
investigational material(s)
Generic name etc : LY3039478
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational materia
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic. -In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate. -Performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale. -Adequate organ function, including hematologic, hepatic, and renal. -Estimated life expectancy of more than or equal to 12 weeks.
Exclusion criteria
Exclusion criteria: -Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively. -Have serious preexisting medical conditions. -Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea. -Have an active bacterial, fungal, and/or known viral infection. -Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.
Outcome results
None listed